CA2180651A1 - Heterocycles phenyliques utilises comme inhibiteurs de cox-2 - Google Patents

Heterocycles phenyliques utilises comme inhibiteurs de cox-2

Info

Publication number
CA2180651A1
CA2180651A1 CA002180651A CA2180651A CA2180651A1 CA 2180651 A1 CA2180651 A1 CA 2180651A1 CA 002180651 A CA002180651 A CA 002180651A CA 2180651 A CA2180651 A CA 2180651A CA 2180651 A1 CA2180651 A1 CA 2180651A1
Authority
CA
Canada
Prior art keywords
phenyl
furanone
methylsulfonyl
pharmaceutically acceptable
so2me
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002180651A
Other languages
English (en)
Inventor
Yves Ducharme
Jacques Yves Gauthier
Petpiboon Prasit
Yves Leblanc
Zhaoyin Wang
Serge Leger
Michel Therien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/179,467 external-priority patent/US5474995A/en
Application filed by Individual filed Critical Individual
Publication of CA2180651A1 publication Critical patent/CA2180651A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C07C311/49—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/58—One oxygen atom, e.g. butenolide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention se rapporte à un nouveau composé de la formule (I), utilisé dans le traitement des maladies induites par cyclooxygénase-2 (COX-2). L'invention se rapporte également à certaines compositions pharmaceutiques destinées au traitement des maladies induites par cyclooxygénase-2 et comprenant les composés de la formule (I).
CA002180651A 1994-01-10 1994-12-19 Heterocycles phenyliques utilises comme inhibiteurs de cox-2 Abandoned CA2180651A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US179,467 1994-01-10
US08/179,467 US5474995A (en) 1993-06-24 1994-01-10 Phenyl heterocycles as cox-2 inhibitors

Publications (1)

Publication Number Publication Date
CA2180651A1 true CA2180651A1 (fr) 1995-07-13

Family

ID=22656713

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002180651A Abandoned CA2180651A1 (fr) 1994-01-10 1994-12-19 Heterocycles phenyliques utilises comme inhibiteurs de cox-2

Country Status (12)

Country Link
EP (1) EP0739340A1 (fr)
JP (1) JP2788677B2 (fr)
CN (1) CN1143365A (fr)
AU (1) AU1269495A (fr)
BG (1) BG63082B1 (fr)
BR (1) BR9408478A (fr)
CA (1) CA2180651A1 (fr)
FI (1) FI108792B (fr)
HU (1) HUT74986A (fr)
NO (1) NO960393L (fr)
SG (1) SG43841A1 (fr)
WO (1) WO1995018799A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
AU715676B2 (en) * 1993-03-12 2000-02-10 Merck Frosst Canada & Co. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5474995A (en) 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5585504A (en) * 1994-09-16 1996-12-17 Merck & Co., Inc. Process of making cox-2 inhibitors having a lactone bridge
US6593361B2 (en) 1995-07-19 2003-07-15 Merck & Co Inc Method of treating colonic adenomas
US5968974A (en) 1995-07-19 1999-10-19 Merck & Co., Inc. Method of treating colonic adenomas
ES2220983T3 (es) * 1995-07-19 2004-12-16 MERCK & CO., INC. Procedimiento de tratamiento de adenomas de colon.
AU775030B2 (en) * 1996-05-17 2004-07-15 Merck Frosst Company Compositions for a once a day treatment of cyclooxygenase-2 mediated diseases
BR9709097A (pt) * 1996-05-17 1999-08-03 Merck & Co Inc Composição farmacêutica para o tratamento de doenças mediadas por ciclooxigenase processo para tratar uma doença inflamatória suscetível de tratamento com um agente antinflamatório n o esteróide uso e forma oral de dose unitária
GB9615867D0 (en) * 1996-07-03 1996-09-11 Merck & Co Inc Process of preparing phenyl heterocycles useful as cox-2 inhibitors
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
DE69825154T2 (de) * 1997-03-14 2005-07-21 Merck Frosst Canada & Co, Kirkland Pyridazinone als inhibitoren von cyclooxygenase-2
US6004960A (en) * 1997-03-14 1999-12-21 Merck Frosst Canada, Inc. Pyridazinones as inhibitors of cyclooxygenase-2
ATE231504T1 (de) * 1997-04-11 2003-02-15 Grelan Pharmaceutical Co Pyrazolderivate und sie enthaltende cox- inhibitoren
WO1998051667A1 (fr) * 1997-05-16 1998-11-19 Chugai Seiyaku Kabushiki Kaisha Derives d'indole et derives de mono- et diazaindole
EP1510519B1 (fr) 1997-09-05 2006-02-15 Glaxo Group Limited Compositions pharmaceutiques contenant dérivés de 2,3-diaryl-pyrazolo(1,5-b)pyridazine
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
SA99191255B1 (ar) 1998-11-30 2006-11-25 جي دي سيرل اند كو مركبات سيليكوكسيب celecoxib
WO2001056596A1 (fr) 2000-02-04 2001-08-09 Children's Hospital Research Foundation Utilisation de lipase acide lysosomiale pour traiter l'atherosclerose et des maladies associees
US6465509B2 (en) * 2000-06-30 2002-10-15 Merck Frosst Canada & Co. Pyrones as inhibitors of cyclooxygenase-2
DE10133665A1 (de) * 2001-07-11 2003-01-30 Boehringer Ingelheim Pharma Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Herstellung
HUE039881T2 (hu) 2002-05-09 2019-02-28 Brigham & Womens Hospital Inc 1L1RL-1, mint egy kardiovaszkuláris betegség-marker
EP1534683A4 (fr) 2002-06-27 2005-08-24 Nitromed Inc Inhibiteurs selectifs de la cyclooxygenase 2, compositions associees et methodes d'utilisation
EP1663184A2 (fr) 2003-08-29 2006-06-07 The Brigham And Women's Hospital, Inc. Inhibiteurs de la necrose cellulaire
KR20050051729A (ko) * 2003-11-28 2005-06-02 일양약품주식회사 사이클로 옥시게나제-2 억제제인 페닐 헤테로사이클의제조방법
DE102004027912A1 (de) 2004-06-09 2005-12-29 Grünenthal GmbH Substituierte Cyclopenten-Verbindungen
CA2624601C (fr) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Pertinence de niveaux obtenus de marqueurs d'inflammation generalisee a la suite d'un traitement
US7521435B2 (en) 2005-02-18 2009-04-21 Pharma Diagnostics, N.V. Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same
AP2896A (en) 2005-05-31 2014-05-31 Mylan Lab Inc Compositions comprising nebivolol
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
PT3279663T (pt) 2006-03-15 2021-09-24 Brigham & Womens Hospital Inc Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias
US20080057590A1 (en) 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
AU2008242764B2 (en) 2007-04-18 2013-10-24 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
GB2462022B (en) 2008-06-16 2011-05-25 Biovascular Inc Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
SG182821A1 (en) 2010-02-01 2012-08-30 Hospital For Sick Children Remote ischemic conditioning for treatment and prevention of restenosis
SG10201502031XA (en) 2010-03-31 2015-05-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
US9265772B2 (en) 2012-05-11 2016-02-23 Reset Therapeutics, Inc. Carbazole-containing sulfonamides as cryptochrome modulators
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
CA3113353A1 (fr) 2018-09-19 2020-03-26 Modernatx, Inc. Lipides peg de haute purete et leurs utilisations
US20220047518A1 (en) 2018-09-19 2022-02-17 Moderna TX, Inc. Peg lipids and uses thereof
CA3119728A1 (fr) 2018-11-21 2020-05-28 Tremeau Pharmaceuticals, Inc. Formes purifiees de rofecoxib et procedes de fabrication et d'utilisation
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2012716A1 (fr) * 1989-03-22 1990-09-22 Akito Tanaka Composes de thiazole, procede de preparation et compose pharmaceutique les contenant
WO1991016055A1 (fr) * 1990-04-17 1991-10-31 Allergan, Inc. 2(5h)-furanones substituees dans les positions 5 et/ou 4, utilisees comme agents anti-inflammatoires
GB9012936D0 (en) * 1990-06-11 1990-08-01 Fujisawa Pharmaceutical Co Thiophene derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
EP0759432A1 (fr) * 1993-01-15 1997-02-26 G.D. Searle & Co. Utilisation de médicaments contenant des furannes 3,4-diaryles et leurs analogues pour le traitement des conditions de la peau
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
SK20396A3 (en) * 1993-08-19 1997-03-05 Warner Lambert Co Substituted 2(5h)furanone, 2(5h)thiophenone or 2(5h)pyrrolone derivatives and pharmaceutical compositions on their base

Also Published As

Publication number Publication date
JPH09506631A (ja) 1997-06-30
CN1143365A (zh) 1997-02-19
BG63082B1 (bg) 2001-03-30
BR9408478A (pt) 1997-08-26
WO1995018799A1 (fr) 1995-07-13
NO960393D0 (no) 1996-01-30
SG43841A1 (en) 1997-11-14
HUT74986A (en) 1997-03-28
BG100350A (bg) 1996-12-31
FI962800A0 (fi) 1996-07-09
NO960393L (no) 1996-07-09
JP2788677B2 (ja) 1998-08-20
HU9601875D0 (en) 1996-09-30
EP0739340A1 (fr) 1996-10-30
FI962800A (fi) 1996-09-06
AU1269495A (en) 1995-08-01
FI108792B (fi) 2002-03-28

Similar Documents

Publication Publication Date Title
CA2180651A1 (fr) Heterocycles phenyliques utilises comme inhibiteurs de cox-2
US6239173B1 (en) 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor
US6329421B1 (en) Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5409944A (en) Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2206978A1 (fr) Diaryl-2-(5h)-furanones inhibiteurs de cox-2
AU706518B2 (en) Bisarylcyclobutene derivates as cyclooxygenase inhibitors
WO1997028121A1 (fr) Styrenes alcoyles utilises en tant que precurseurs d'inhibiteurs de cox-2
US6486194B2 (en) Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
JP3490406B2 (ja) シクロオキシゲナーゼ−２阻害剤としてのフェニルヘテロ環
CA2244140C (fr) Styrenes alcoyles utilises en tant que precurseurs d'inhibiteurs de cox-2
CA2369333A1 (fr) Oxydes de diphenyle-1,2,3-thiadiazole-3, compositions et procedes d'utilisation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead